BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — BTC Health — FY2025 Earnings Presentation
22 slides from BTC Health Ltd Registered's earnings presentation, Aug 28, 2025
Slide 1: Investor Presentation – FY25 Results
For personal use only Improving patients’ lives through global BTC Health Limited (ASX:BTC) Investor Presentation – FY25 Results medical innovation August 2025
Slide 2: Disclaimer
Disclaimer Summary information This Presentation contains summary information about BTC health, and its activities current as at 28 August 2025. The information in the presentation is of a general For personal use only nature and does not purport to be complete or comprise all information which a sh
Slide 3: Our mission statement
For personal use only “Our mission is to distribute innovative and class-leading medical products, collaborating closely with healthcare professionals. By doing so, we empower patients to resume their daily passions and pursuits.” Executive Chairman Dr. Richard Treagus
Slide 4: Background
Background BTC Health is a listed company that supplies specialised medical products and services for acute pain management, neurospinal, cardiovascular, intensive care and the pharmaceutical sectors. For personal use only Its strategy is to expand the product range across high-demand therapeutic ar
Slide 5: Group structure
Group structure For personal use only BTC Health Ltd 100% 100% 100% BTC Speciality BTC Cardio PL BTC Pharma PL Health PL Post-Operative Specialised Neuro-Spinal Cardio-thoracic Critical Care Pain Pharmaceuticals BTC health is a registered Pooled Development Fund (PDF) in Australia. It is a type of v
Slide 6: Statutory Results - FY25 vs FY24
Statutory Results - FY25 vs FY24 FY25 ($) FY24 ($) For personal use only Interest income 9,960 16,360 Gain on investments 4,646,820 1,714,809 Corporate expenses 675,482 675,882 Profit before tax 3,981,298 1,055,287 Profit for the period 3,981,298 1,055,287 The increase in gain on investments reflect
Slide 7: Our strategy
Our strategy For personal use only Our Advantage The Growth Opportunity • Only dedicated specialist medical • Rising consumer and government product company on the ASX. healthcare spending. • World-class capabilities, ISO 13485 • Ageing populations and rapid certification, deep industry expertise, a
Slide 8: Infrastructure and customer reach
Infrastructure and customer reach BTC health – Distribution and Sales Network Our Tier 1 Customers For personal use only Daily deliveries to 500+ hospitals (metro) and 48hr delivery (regional) 8
Slide 9: Direct access to the hospital market
Direct access to the hospital market For personal use only 1,450+ Hospitals Australasia wide Australian Market New Zealand Market Public Hospitals Public Hospitals 68% of private • 695 Public Hospitals • 84 Public Hospitals hospital funding in • $67 billion expenditure in public • $12.5 billion expe
Slide 10: FY25 financial highlights
BTC Health and investee companies FY25 financial highlights • YoY double digit revenue growth. Revenue Gross Profit For personal use only • Strong contribution from Cardio and ECMO $10.2m $4.3m products, with a $5m (5-year) Royal Children’s Hospital tender awarded in September 2024. A +25% YoY +19%
Slide 11: FY25 Key Financial Metrics
FY25 Key Financial Metrics Group Sales Gross Profit Gross Margin $ millions $ millions 45% $10.2 $4.3 For personal use only 43% 42% $3.6 40% $8.2 $3.3 39% $7.7 $7.8 $3.1 $7.2 $2.9 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Gross Operating Costs Gross EBITDA EBITDA of
Slide 12: Milestones achieved + delivery against goals in FY25
Milestones achieved + delivery against goals in FY25 Milestones Delivery Against Goals For personal use only WINNING ECMO BUSINESS • BTC to supply ECMO equipment, consumables and services to Melbourne’s Double-digit revenue growth of Royal Children’s Hospital after it won a $5m ECMO contract 25% ach
Slide 13: Operations update
Operations update Diversifying our products reduces dependence on any single product or supplier. For personal use only • Successful supplier and product diversification, with four new partnership agreements and >240 active product lines. • Implementation of ECMO equipment at Royal Childrens’ Hospit
Slide 14: Continuing Momentum into FY26
Continuing Momentum into FY26 Areas of Focus For personal use only • Winning additional ECMO hospital contracts • Increasing Perceval Plus heart valve utilisation in established centres • Expanding customer base with the neurospinal products • Converting infusion pump users across to Rhythmic and El
Slide 15: Appendices
For personal use only Appendices 15
Slide 16: Post-operative pain
Post-operative pain For personal use only Infusion pumps and consumables In 2022, there were 51,894 hip replacements in Australia and 67,742 knee replacements. Both procedures involve a post-operative recovery process where an electronic, portable infusion pump is applied for acute and chronic drug
Slide 17: Neuro-spinal
Neuro-spinal IZI Medical For personal use only Innovative medical devices and single-use products used in radiology and oncology, radiation therapy, neuro-spine, and image-guided surgery procedures. Ilumark Products focusing on sterile single-use retro-reflective marker spheres for image-guided and
Slide 18: Cardiothoracic and critical care
Cardiothoracic and critical care CPB - Cardiopulmonary Bypass For personal use only In 2022 across public and private hospitals in Australia, there were • 12,700 coronary artery bypass graft procedures • 12,000 heart valve repair or replacement procedures, and • 129 heart transplants Each procedure
Slide 19: Cardiothoracic and critical care
Cardiothoracic and critical care PEARS For personal use only BTC Cardio entered into a distribution agreement with Exstent in FY24 to distribute its ExoVasc medical device, aka Personalised External Aortic Root Support (PEARS). 50 patients received an ExoVasc device implant in 2023, and BTC forecast
Slide 20: Heart Valves
Heart Valves AORTIC BTC Cardio entered a distribution agreement with Corcym to For personal use only distribute its sutureless Perceval Plus tissue valve and the Carbomedics mechanical valve. >300 patients received a Perceval tissue heart valve in 2024 in public and private hospitals in Australia an
Slide 21: Pharmaceutical
Pharmaceutical For personal use only Bronchitol and Aridol Bronchitol is a PBS-listed treatment for Cystic Fibrosis (CF), a disease that affects more than 3,700 people in Australia and requires ongoing treatment. Bronchitol is manufactured in Australia with BTC Pharma having acquired the exclusive A
Slide 22: Improving Australian lives through global medical innovation
Improving Australian lives through global medical innovation For personal use only For more information, please contact: BTC Health Limited Dr Richard Treagus Salesh Balak Executive Chairman Chief Financial Officer +61 417 520 509 +61 414 508 852 rtreagus@btchealth.com.au sbalak@btchealth.com.au 22